Over the past 12 months, 0 insiders at BeiGene, Ltd. filed 0 open-market SEC Form 4 transactions on BGNE: 0 purchases worth $0 and 0 sales worth $0. Insiders have been mixed over this period. The most recent filing was on .
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| May 13, 25 | Xiaodong WangDirector,Other | SELL | 21.2K | $225.68 | $4.7M |
| Apr 14, 25 | Xiaodong WangDirector,Other | SELL | 15.0K | $249.45 | $3.6M |
| Apr 1, 25 | Xiaobin WuPresident, COO & GM China | SELL | 28.3K | $283.79 | $7.9M |
| Mar 18, 25 | Xiaodong WangDirector,Other | SELL | 11.2K | $264.01 | $2.9M |
| Mar 14, 25 | Xiaobin WuPresident, COO & GM China | SELL | 0 | - | $0 |
| Mar 10, 25 | John OylerChief Executive Officer | SELL | 9.3K | $246.85 | $2.3M |
| Mar 7, 25 | John OylerChief Executive Officer | SELL | 13.9K | $256.10 | $3.4M |
| Mar 6, 25 | John OylerChief Executive Officer | SELL | 13.6K | $264.27 | $3.5M |
| Mar 5, 25 | Xiaobin WuPresident, COO & GM China | SELL | 22.5K | $263.00 | $5.9M |
| Mar 4, 25 | Xiaodong WangDirector,Other | SELL | 2.0K | $257.41 | $505K |
| Mar 3, 25 | John OylerChief Executive Officer | SELL | 19.2K | $249.25 | $4.7M |
| Feb 28, 25 | Xiaobin WuPresident, COO & GM China | SELL | 0 | - | $0 |
| Feb 27, 25 | Chan Henry LeeSVP, General Counsel | SELL | 1.2K | $275.00 | $331K |
| Feb 21, 25 | Chan Henry LeeSVP, General Counsel | SELL | 598 | $260.22 | $155K |
| Feb 21, 25 | Lai WangGlobal Head of R&D | SELL | 1.8K | $260.17 | $461K |
| Feb 20, 25 | Xiaobin WuPresident, COO & GM China | SELL | 21.3K | $240.07 | $5.1M |
| Feb 18, 25 | Xiaobin WuPresident, COO & GM China | SELL | 19.6K | $242.08 | $4.7M |
| Feb 4, 25 | Xiaodong WangDirector,Other | SELL | 17.8K | $228.04 | $4.0M |
| Jan 7, 25 | Xiaodong WangDirector,Other | SELL | 19.3K | $179.18 | $3.4M |
| Dec 10, 24 | Xiaodong WangDirector,Other | SELL | 10.0K | $195.67 | $1.8M |
| Dec 9, 24 | Baker Brothers Life Sciences LpDirector | SELL | 917.0K | $208.01 | $171.0M |
| Dec 6, 24 | Xiaobin WuPresident, COO & GM China | SELL | 0 | - | $0 |
| Nov 26, 24 | Xiaodong WangDirector,Other | SELL | 12.3K | $191.96 | $2.4M |
| Oct 8, 24 | John OylerChief Executive Officer | SELL | 2.8K | $236.37 | $650K |
| Sep 30, 24 | Chan Henry LeeSVP, General Counsel | SELL | 1.2K | $237.10 | $285K |
| Sep 27, 24 | Lai WangGlobal Head of R&D | SELL | 5.0K | $220.35 | $1.1M |
| Sep 19, 24 | Xiaobin WuPresident, COO & GM China | SELL | 4.5K | $200.14 | $901K |
| Sep 17, 24 | Xiaobin WuPresident, COO & GM China | SELL | 500 | $200.00 | $100K |
| Sep 3, 24 | Titus B. BallPrincipal Accounting Officer | SELL | 137 | $189.94 | $26K |
| Sep 3, 24 | Xiaobin WuPresident, COO & GM China | SELL | 2.3K | $192.04 | $433K |
| Jul 30, 24 | Chan Henry LeeSVP, General Counsel | SELL | 834 | $160.57 | $134K |
| Jul 1, 24 | Julia Aijun WangChief Financial Officer | SELL | 472 | $143.90 | $68K |
| Jun 24, 24 | John OylerChief Executive Officer | SELL | 2.4K | $160.12 | $381K |
| Jun 24, 24 | Julia Aijun WangChief Financial Officer | SELL | 899 | $155.66 | $140K |
| Jun 24, 24 | Lai WangGlobal Head of R&D | SELL | 1.1K | $161.10 | $170K |
| Jun 24, 24 | Xiaobin WuPresident, COO & GM China | SELL | 1.0K | $161.27 | $165K |
| Jun 18, 24 | Lai WangGlobal Head of R&D | SELL | 841 | $153.75 | $129K |
| Jun 18, 24 | Xiaobin WuPresident, COO & GM China | SELL | 1.1K | $156.80 | $172K |
| Jun 17, 24 | Chan Henry LeeSVP, General Counsel | SELL | 208 | $159.74 | $33K |
| Jun 17, 24 | John OylerChief Executive Officer | SELL | 608 | $159.91 | $97K |
| Jun 17, 24 | Julia Aijun WangChief Financial Officer | SELL | 314 | $159.74 | $50K |
| Jun 17, 24 | Lai WangGlobal Head of R&D | SELL | 485 | $159.90 | $77K |
| Jun 17, 24 | Xiaobin WuPresident, COO & GM China | SELL | 627 | $159.00 | $100K |
| Apr 11, 24 | John OylerChief Executive Officer | SELL | 5.0K | $147.74 | $732K |
| Apr 10, 24 | John OylerChief Executive Officer | SELL | 12.5K | $150.85 | $1.9M |
| Apr 9, 24 | John OylerChief Executive Officer | SELL | 7.9K | $154.21 | $1.2M |
| Mar 13, 24 | John OylerChief Executive Officer | SELL | 6.0K | $184.17 | $1.1M |
| Mar 12, 24 | John OylerChief Executive Officer | SELL | 15.5K | $169.05 | $2.5M |
| Feb 29, 24 | Julia Aijun WangChief Financial Officer | SELL | 397 | $167.08 | $66K |
| Nov 14, 23 | Baker Brothers Life Sciences LpDirector,TenPercentOwner | SELL | 1.01M | $180.50 | $182.1M |
Over the past 12 months, insiders at BeiGene, Ltd. filed 0 open-market purchases worth $0 and 0 sales worth $0 on BGNE, which makes them mixed over the period. The most recent Form 4 was filed on .
0 different insiders at BeiGene, Ltd. filed open-market SEC Form 4 transactions on BGNE over the last 12 months.
InsiderTape plots every BGNE insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every BeiGene, Ltd. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →